Business
Utility Study
Utility Study.
About this update from Renalytix Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 6483A\n Renalytix AI PLC\n 03 June 2021\n \n \n \n \n Renalytix AI plc\n \n \n \n (\"Renalytix\" or the \"Company\")\n \n \n \n \n \n \n Utility Study Indicates KidneyIntelX Risk Assessment can Address Treatment Ambiguity in Primary Care \n \n \n \n \n \n Clinicians affirm need for accurate early-stage diabetic kidney disease risk assessment to improve patient outcomes and reduce healthcare costs\n \n \n \n \n \n \n NEW YORK, June 3, 2021 - \n \n \n Renalytix AI plc\n \n (LSE: RENX) (NASDAQ: RNLX) today announced results from a new utility study. The study confirmed the importance of risk assessment testing in addressing treatment ambiguity in the early stages of diabetic kidney disease (DKD) and improving patient engagement and adherence, two major barriers to slowing or preventing DKD progression and preserving kidney health. In clinical studies, KidneyIntelX has shown to accurately predict progression of DKD, suggesting that KidneyIntelX risk assessment could support primary care physicians in making appropriate treatment decisions and slowing or preventing DKD progression.\n \n \n \n \n \n In this qualitative study involving 16 primary care physicians, 100% of clinician study participants confirmed that early-stage kidney risk assessment, like that provided by KidneyIntelX, will help to address suboptimal therapy, which can lead to rapid progression, increased hospital admissions, emergency room visits, potential kidney failure, need for dialysis, decreased quality of life, and increased costs. \n \n \n \n \n \n \n Dr. Joseph Vassalotti, Chief Medical Officer of the National Kidney Foundation (NKF) and Clinical Professor at the Icahn School of Medicine Mount Sinai Health System commented,\n \n \n \"The NKF believes primary care physicians have the power to change the outcome for the vast majority of individuals with early-stage kidney disease who are at risk for progressive kidney disease. Americans living with kidney diseases universally express the preference for early diagnosis. This study confirms the compelling data presented at this year's NKF Spring Clinical Meeting that KidneyIntelX could be widely adopted by primary care physicians (PCPs) and could alter how at-risk populations with type-2 diabetes can receive early education and the...